In phase I and II clinical studies, pamiparib demonstrated antitumour activity and induced durable responses in patients with epithelial ovarian cancer (EOC) and HER2-negative (HER2−) breast cancer with germline BRCAmut [22–25]. Here, ERBB2 is linked to breast carcinoma.